[go: up one dir, main page]

WO2006069000A3 - Klf2 as a mediator of statin activity - Google Patents

Klf2 as a mediator of statin activity Download PDF

Info

Publication number
WO2006069000A3
WO2006069000A3 PCT/US2005/045946 US2005045946W WO2006069000A3 WO 2006069000 A3 WO2006069000 A3 WO 2006069000A3 US 2005045946 W US2005045946 W US 2005045946W WO 2006069000 A3 WO2006069000 A3 WO 2006069000A3
Authority
WO
WIPO (PCT)
Prior art keywords
klf2
activity
mediator
compounds
identifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/045946
Other languages
French (fr)
Other versions
WO2006069000A2 (en
Inventor
Mukesh K Jain
Sucharita Senbanerjee
Pallab Banerjee
Zhiyong Lin
Gillermo Garcia-Cardena
Michael A Gimbrone Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of WO2006069000A2 publication Critical patent/WO2006069000A2/en
Anticipated expiration legal-status Critical
Publication of WO2006069000A3 publication Critical patent/WO2006069000A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to methods for identifying compounds that mimic or inhibit the therapeutic effect of statins. The compounds are identified using assays of the transcription factor KLF2. The invention also includes methods for creating or identifying endothelial cells with low KLF2 activity which will be resistant to statin treatment and for increasing KLF2 activity by transfecting cells with expression vectors.
PCT/US2005/045946 2004-12-21 2005-12-20 Klf2 as a mediator of statin activity Ceased WO2006069000A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63766404P 2004-12-21 2004-12-21
US60/637,664 2004-12-21
US65738205P 2005-03-02 2005-03-02
US60/657,382 2005-03-02

Publications (2)

Publication Number Publication Date
WO2006069000A2 WO2006069000A2 (en) 2006-06-29
WO2006069000A3 true WO2006069000A3 (en) 2007-08-09

Family

ID=36602241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/045946 Ceased WO2006069000A2 (en) 2004-12-21 2005-12-20 Klf2 as a mediator of statin activity

Country Status (1)

Country Link
WO (1) WO2006069000A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1614429A4 (en) * 2003-04-17 2007-05-02 Kowa Co PROMOTER OF GENE EXPRESSION LKLF / KLF2
WO2008132458A1 (en) * 2007-04-30 2008-11-06 Inion Limited Compositions useful in the modulation of immune responses and the treatment or prevention of inflammatory responses and related methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039956A2 (en) * 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039956A2 (en) * 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEKKER ET AL.: "Prolonged fluid shear stress induces a distinct set of endothelial cell genes most specifically lung Kruppel-factor (KLF2)", BLOOD, vol. 100, no. 5, September 2002 (2002-09-01), pages 1689 - 1698, XP002425163, DOI: doi:10.1182/blood-2002-01-0046 *
WANI ET AL.: "cDNA isolation, genomic structure, regulation, and chromosomal localization of human lung Kruppel-like factor", GENOMICS, vol. 60, 1999, pages 78 - 86, XP004444838, DOI: doi:10.1006/geno.1999.5888 *

Also Published As

Publication number Publication date
WO2006069000A2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
DE602006012539D1 (en) PREPARATION OF PERACIDES USING AN ENZYME WITH PERHYDROLYSIS ACTIVITY
WO2006031994A3 (en) Monomeric immunoglobulin fc domains
WO2006092213A8 (en) Pyrazolylcarboxanilides
ATE546044T1 (en) USE OF ALKYL CARBONIC ACID AMIDES AS PENETRATION PROMOTERS
WO2006105448A3 (en) Proliferation of muc1 expressing cells
WO2006015124A3 (en) Fused ring heterocycle kinase modulators
WO2010148223A3 (en) Anti-vegf antibodies and their uses
TNSN07027A1 (en) Pyrrolo-pyridine kinase modulators
WO2007041610A3 (en) Genes and proteins associated with angiogenesis and uses thereof
GB2489187A (en) Compositions,methods and related uses for cleaving modified DNA
EP2374884A3 (en) Human miRNAs isolated from mesenchymal stem cells
CY1112877T1 (en) EXPLOSIVES OF HIGH ACTIVITY
WO2007140390A3 (en) Method for modulating hair growth
WO2009083790A8 (en) 'apoptosis inducing positive control for expression modulating experiments'
WO2006069000A3 (en) Klf2 as a mediator of statin activity
ATE488591T1 (en) NEW L-LYSINE-INDUCABLE PROMOTER
DE502006005179D1 (en) METHOD FOR THE ENANTIOSELECTIVE ENZYMATIC REDUCTION OF KETOVER BINDINGS
DE502005003027D1 (en) ELECTROLYSIS CELL FOR THE MANUFACTURE OF ALKALIMETALL
ATE542796T1 (en) N-SULFONYLCARBOXIMIDAMIDE COMPOUNDS AS APOPTOSIS PROMOTERS
WO2006132739A3 (en) Novel chemical compounds
TW200639195A (en) Curable composition and its uses
WO2005070042A8 (en) Novel chemical compounds
ATE519364T1 (en) CRYOPRESERVATION OF HEPATOCYTES
WO2005079378A3 (en) Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
DK1856249T3 (en) Growth factor mutants with enhanced biological activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05854623

Country of ref document: EP

Kind code of ref document: A2